Korean J Physiol Pharmacol.  2021 Nov;25(6):525-532. 10.4196/kjpp.2021.25.6.525.

Roles for α₁-adrenoceptors during contractions by electrical field stimulation in mouse vas deferens

• Alsufyani HA
• Docherty JR

• KMID: 2521478
• DOI: http://doi.org/10.4196/kjpp.2021.25.6.525

Abstract

We have investigated the relative roles of α₁-adrenoceptors and purinoceptors in contractions to low and high frequency stimulation of the mouse vas deferens, in terms of the time course of responses. In separate experiments, isometric contractile responses were obtained to 10 pulses at 1 Hz and 40 pulses at 10 Hz. Responses to 1 Hz stimulation consisted of a series of discrete peaks. The α_1A -adrenoceptor antagonist RS100329 (10 ^–9 M–10 ^–7 M) significantly reduced the response to the first pulse, the α_1D-adrenoceptor antagonist BMY7378 (10 ^–7 M–10^–6 M) significantly reduced the response to the first two pulses, and the non-selective α₁-adrenoceptor antagonist prazosin (10^–8 M) reduced the response to the first 4 pulses at 1 Hz. Responses to 10 Hz stimulation consisted of an early peak response and a maintained plateau response. RS100329 significantly reduced the peak response but did not significantly affect the plateau response. Prazosin, significantly reduced both the peak and plateau responses. The α_1A-adrenoceptor antagonist RS17053 in high concentrations reduced mainly the plateau response leaving a clear early peak response. The plateau response of contraction was almost abolished by the purinoceptor antagonist suramin. These results suggest that there is a relatively minor early α_1D -adrenoceptor and a larger early α_1A -adrenoceptor component to stimulationevoked contractions of mouse vas deferens, but the major α₁ -adrenoceptor component is revealed by prazosin to be α_1B -adrenoceptor mediated. α_1B -Adrenoceptor activation probably facilitates contractions mediated by other α₁-adrenoceptors and by purinoceptors. These results suggest that combined non-selective α₁-adrenoceptor blockade, particularly α_1B -adrenoceptor blockade, in addition to P2X1-purinoceptor blockade is useful in reducing male fertility.

Keyword

Adrenergic; Fertility; Muscle; smooth; Neuromuscular junction; Vas deferens

Figure

• 

  Fig. 1 Effects of vehicle and antagonists on isometric contractions of mouse vas deferens produced by 10 pulses at 1 Hz, expressed as tension in grams. (A) Original recording of isometric contractions obtained to field stimulation in mouse vas deferens with 10 pulses at 1 Hz. The vertical axis shows tension in grams. The horizontal axis shows pulse number at 1 Hz and the time between each pulse is 1 sec. The response to the first pulse is clearly shown. (B–E) The effects of (B) vehicle (veh) (4 additions), (C) BMY7378 (BMY) (10 nM–10 µM), (D) RS100329 (1 nM–1 µM) and (E) prazosin (praz) (1 nM–1 µM) on isometric contractions to each pulse of 10 pulse field stimulation at 1 Hz in mouse vas deferens, expressed as absolute tension in grams. Values are presented as mean ± SEM from 6 experiments. Statistical tests were carried out on data expressed as a percentage of control (see ).

• 

  Fig. 2 Effects of vehicle and antagonists on isometric contractions of mouse vas deferens produced by 10 pulses at 1 Hz, expressed as % of control. The effects of (A) vehicle (veh) (4 additions), (B) BMY7378 (BMY) (10 nM–10 µM), (C) RS100329 (1 nM–1 µM) and (D) prazosin (praz) (1 nM–1 µM) on isometric contractions to each pulse of 10 pulse field stimulation at 1 Hz in mouse vas deferens, expressed as % of control response (see for responses expressed as absolute tension). Values are presented as mean ± SEM from 6 experiments. Responses in the presence of antagonist were compared with the effects of respective vehicle by 2 way analysis of variance and Bonferroni post-hoc test. Asterisks denote effects of antagonist significantly different from the effects of vehicle in response to a given pulse, and are colour coded to match the antagonist concentration symbol colour: *p < 0.05; **p < 0.01; ***p < 0.001.

• 

  Fig. 3 Effects of vehicle and antagonists on isometric contractions of mouse vas deferens produced by 40 pulses at 10 Hz, expressed as tension in grams. (A) Original recordings of isometric contraction obtained to field stimulation in mouse vas deferens with 40 pulses at 10 Hz. The vertical axis shows tension in grams. The horizontal axis shows time in sec, with stimulation at 10 Hz beginning at time zero and ending at 4 sec. (B–G) The effects of (B) vehicle (veh) (4 additions), (C) BMY7378 (BMY) (10 nM–1 µM), (D) RS100329 (0.1 nM–100 nM), (E) prazosin (praz) (1 nM–1 µM) and (F) RS17053 (100 nM–10 µM) on isometric contractions to field stimulation with 40 pulses at 10 Hz in mouse vas deferens, expressed as absolute tension in grams. In (G) responses in the presence suramin (sur) 100 µM and nifedipine (nif) 100 µM are shown. Values are presented as mean ± SEM from 6 experiments, except for suramin and nifedipine, where n = 5, and RS17053, where n = 4. Statistical tests were carried out on data expressed as a percentage of control (see ).

• 

  Fig. 4 Effects of vehicle and antagonists on isometric contractions of mouse vas deferens produced by 40 pulses at 10 Hz, expressed as % of control. The effects of (A) vehicle (veh) (4 additions), (B) BMY7378 (BMY) (10 nM–1 µM), (C) RS100329 (0.1 nM–100 nM), (D) prazosin (praz) (1 nM–1 µM) and (E) RS17053 (100 nM–10 µM) on isometric contractions to field stimulation with 40 pulses at 10 Hz in mouse vas deferens, expressed as a percentage of the respective control response (see for responses expressed as absolute tension). Values are presented as mean ± SEM from 6 experiments, except for (E), where n = 4. Responses in the presence of antagonist were compared with the effects of respective vehicle by 2 way analysis of variance and Bonferroni post-hoc test. Asterisks denote effects of antagonist significantly different from the effects of vehicle at a given time point, and are colour coded to match the antagonist concentration symbol colour: *p < 0.05; **p < 0.01; ***p < 0.001.

Reference

1. Young JS, Brain KL, Cunnane TC. 2007; Electrical and optical study of nerve impulse-evoked ATP-induced, P2X-receptor-mediated sympathetic neurotransmission at single smooth muscle cells in mouse isolated vas deferens. Neuroscience. 148:82–91. DOI: 10.1016/j.neuroscience.2007.05.044. PMID: 17629625. PMCID: PMC2151008.

2. Bexis S, Cleary L, McGrath JC, Tanoue A, Tsujimoto G, Docherty JR. 2008; Alpha_1D-adrenoceptors mediate nerve and agonist-evoked contractions in mouse vas deferens: evidence obtained from knockout technology. Auton Autacoid Pharmacol. 28:81–85. DOI: 10.1111/j.1474-8673.2008.00420.x. PMID: 18598289.

3. Docherty JR. 2013; Prazosin has low potency at α_1A-adrenoceptors and high potency at α_1D-adrenoceptors in rat vas deferens. Auton Autacoid Pharmacol. 33:49–57. DOI: 10.1111/aap.12015. PMID: 24074250.

4. Gorodeski GI. 2015; Purinergic signalling in the reproductive system. Auton Neurosci. 191:82–101. DOI: 10.1016/j.autneu.2015.04.008. PMID: 25981553.

5. White CW, Choong YT, Short JL, Exintaris B, Malone DT, Allen AM, Evans RJ, Ventura S. 2013; Male contraception via simultaneous knockout of α_1A-adrenoceptors and P2X1-purinoceptors in mice. Proc Natl Acad Sci U S A. 110:20825–20830. DOI: 10.1073/pnas.1318624110. PMID: 24297884. PMCID: PMC3870707.

6. Williams TJ, Blue DR, Daniels DV, Davis B, Elworthy T, Gever JR, Kava MS, Morgans D, Padilla F, Tassa S, Vimont RL, Chapple CR, Chess-Williams R, Eglen RM, Clarke DE, Ford AP. 1999; In vitro α₁-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel α_1A -adrenoceptor selective antagonists. Br J Pharmacol. 127:252–258. DOI: 10.1038/sj.bjp.0702541. PMID: 10369480. PMCID: PMC1566006.

7. Goetz AS, King HK, Ward SD, True TA, Rimele TJ, Saussy DL Jr. 1995; BMY 7378 is a selective antagonist of the D subtype of α₁-adrenoceptors. Eur J Pharmacol. 272:R5–R6. DOI: 10.1016/0014-2999(94)00751-R.

8. Docherty JR. 2019; The pharmacology of α1-adrenoceptor subtypes. Eur J Pharmacol. 855:305–320. https://doi.org/10.1016/j.ejphar.2019.04.047. DOI: 10.1016/j.ejphar.2019.04.047. PMID: 31067439.

9. Kenny BA, Miller AM, Williamson IJ, O'Connell J, Chalmers DH, Naylor AM. 1996; Evaluation of the pharmacological selectivity profile of α₁ adrenoceptor antagonists at prostatic α₁ adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol. 118:871–878. DOI: 10.1111/j.1476-5381.1996.tb15480.x. PMID: 8799556. PMCID: PMC1909506.

10. Alsufyani HA, Docherty JR. 2021; Involvement of G proteins and Rho kinase in α₁-adrenoceptor mediated contractions of the rat portal vein. Can J Physiol Pharmacol. 99:654–659. DOI: 10.1139/cjpp-2020-0347. PMID: 33096009.

11. Alsufyani HA, McCormick PA, Docherty JR. 2021; Both α_1B- and α_1A-adrenoceptor subtypes are involved in contractions of rat spleen. Pharmacol Rep. 73:255–260. DOI: 10.1007/s43440-020-00118-x. PMID: 32860192.

12. Cleary L, Slattery J, Bexis S, Docherty JR. 2004; Sympathectomy reveals α_1A- and α_1D-adrenoceptor components to contractions to noradrenaline in rat vas deferens. Br J Pharmacol. 143:745–752. DOI: 10.1038/sj.bjp.0705987. PMID: 15451776. PMCID: PMC1575931.

13. Ford AP, Daniels DV, Chang DJ, Gever JR, Jasper JR, Lesnick JD, Clarke DE. 1997; Pharmacological pleiotropism of the human recombinant α_1A-adrenoceptor: implications for alpha1-adrenoceptor classification. Br J Pharmacol. 121:1127–1135. DOI: 10.1038/sj.bjp.0701207. PMID: 9249248. PMCID: PMC1564783.

14. Marshall I, Burt RP, Green GM, Hussain MB, Chapple CR. 1996; Different subtypes of α_1A-adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053. Br J Pharmacol. 119:407–415. DOI: 10.1111/j.1476-5381.1996.tb16001.x. PMID: 8886428. PMCID: PMC1915842.

15. Seto SW, Bexis S, McCormick PA, Docherty JR. 2010; Actions of thalidomide in producing vascular relaxations. Eur J Pharmacol. 644:113–119. DOI: 10.1016/j.ejphar.2010.06.035. PMID: 20615401.

16. Bültmann R, Trendelenburg M, Tuluc F, Wittenburg H, Starke K. 1999; Concomitant blockade of P2X-receptors and ecto-nucleotidases by P2-receptor antagonists: functional consequences in rat vas deferens. Naunyn Schmiedebergs Arch Pharmacol. 359:339–344. DOI: 10.1007/PL00005360. PMID: 10344533.

17. Mulryan K, Gitterman DP, Lewis CJ, Vial C, Leckie BJ, Cobb AL, Brown JE, Conley EC, Buell G, Pritchard CA, Evans RJ. 2000; Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature. 403:86–89. DOI: 10.1038/47495. PMID: 10638758.

18. Chiba Y, Misawa M. 2004; The role of RhoA-mediated Ca²⁺ sensitization of bronchial smooth muscle contraction in airway hyperresponsiveness. J Smooth Muscle Res. 40:155–167. DOI: 10.1540/jsmr.40.155. PMID: 15655303.

19. Perez DM, Piascik MT, Graham RM. 1991; Solution-phase library screening for the identification of rare clones: isolation of an α_1D-adrenergic receptor cDNA. Mol Pharmacol. 40:876–883.

20. Yono M, Tanaka T, Tsuji S, Hori M, Irie S, Sakata Y, Otani M, Yoshida M, Latifpour J. 2012; A comparison of the expression and contractile function of α₁-adrenoceptors in seminal vesicle and vas deferens from normotensive and hypertensive rats. Eur J Pharmacol. 694:104–110. DOI: 10.1016/j.ejphar.2012.08.005. PMID: 22960063.

21. Cleary L, Vandeputte C, Docherty JR. 2002; Investigation of neurotransmission in vas deferens from α_2A/D-adrenoceptor knockout mice. Br J Pharmacol. 136:857–864. DOI: 10.1038/sj.bjp.0704791. PMID: 12110610. PMCID: PMC1573420.

22. Sanbe A, Tanaka Y, Fujiwara Y, Tsumura H, Yamauchi J, Cotecchia S, Koike K, Tsujimoto G, Tanoue A. 2007; Alpha₁-adrenoceptors are required for normal male sexual function. Br J Pharmacol. 152:332–340. DOI: 10.1038/sj.bjp.0707366. PMID: 17603545. PMCID: PMC2042949.

23. Paz GF, Shilon M, Homonnai ZT. 1984; The possible use of phenoxybenzamine as a male contraceptive drug: studies on male rats. Contraception. 29:189–195. DOI: 10.1016/0010-7824(84)90029-5. PMID: 6723312.

24. Homonnai ZT, Shilon M, Paz GF. 1984; Phenoxybenzamine--an effective male contraceptive pill. Contraception. 29:479–491. DOI: 10.1016/0010-7824(84)90022-2. PMID: 6430643.

25. Ratnasooriya WD, Wadsworth RM. 1990; Impairment of fertility of male rats with prazosin. Contraception. 41:441–447. DOI: 10.1016/0010-7824(90)90043-U. PMID: 2335107.

26. Kjaergaard N, Kjaergaard B, Lauritsen JG. 1988; Prazosin, an adrenergic blocking agent inadequate as male contraceptive pill. Contraception. 37:621–629. DOI: 10.1016/0010-7824(88)90008-X. PMID: 2899490.

27. Mathiew M, Dennis BM, Bennetts F, Su NNE, Nguyen N, Botteon A, Baell JB, Ventura S. 2020; Synthesis of 2-phenyl-5,6,7,8-tetrahydroquinoxaline derivatives and screening for P2X1-purinoceptor antagonist activity in isolated preparations of rat vas deferens, for translation into a male contraceptive. Biol Reprod. 103:323–332. DOI: 10.1093/biolre/ioaa117. PMID: 32648904. PMCID: PMC7526726.